Abstract: A method for inserting an identification modulation code into a printed image. The method has the steps of inserting a start code modulation sequence, followed by the code modulation sequence, and then a stop code modulation sequence. The code is preferably repeated several times throughout the printed image. The modulation sequence can have several levels of subpixel modulation magnitude.

Abstract: A method and apparatus for applying a liner to a pipe is disclosed. The apparatus includes a base assembly having a plurality of guide rails and a shuttle plate attached thereto. The apparatus also includes a motor module attached to an end of the base assembly. An extension arm is connected to a top surface of the shuttle plate. The extension arm has a spray head assembly attached at an opposite end thereof. The extension arm and spray head assembly will move relative to the base assembly of the apparatus. A fast cure coating will be applied via the spray head assembly to the interior surface of a pipe being rehabilitated. The spray head assembly will have an air blow off mechanism therein thus allowing for the tip of the spray head assembly to stay relatively clog free during the fast cure coating operation of the apparatus.

Abstract: An ex-vivo method of treating myeloablation of hematopoietic stem and progenitor cells, particularly myeloablation due to ionizing radiation is disclosed. An ex-vivo method of restoring a depleted population of rapidly proliferating hematopoietic stem cells is also disclosed. The methods comprise co-culturing resistant hematopoietic stem cells in a culture medium comprising a monolayer of endothelial cells and various cytokines. Bone marrow stem cells harvested from animals exposed to 1050 cGy were incapable of providing hematopoietic recovery in secondary irradiated recipients. Bone marrow stem cells harvested from animals exposed to 1050 cGy and then co-cultured×10 days with endothelial cell monolayers showed complete recovery of hematopoietic repopulating capacity which was equivalent to normal BM stem cells.

Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Abstract: This invention relates to porous polymer films and methods for their preparation. In particular the present invention relates to a method for preparing porous polymer films using ATRP or RAFT polymerisation, or using graft polymers prepared by living/controlled polymerisation or using microgels, methods for enhancing the uniformity of pore size in porous polymer films or for preparing porous polymer films having regularly spaced pores of substantially regular pore size, and methods for facilitating the casting of porous polymer films or for controlling or increasing the pore size of porous polymer films.

Abstract: A car cover in a container with a 4-unit suspension system that keeps the tarp from the painted surface of the vehicle while protecting the paint, rubber and interior. Another feature of the invention is its attachments to protect the vehicle from hail or sleet. The tarp, container, and the suspension units will be marketed in 3 different sizes to fit all vehicles including duallys, vans and passenger autos. The tarp container can be hung on a building with 2 removable oval hangers with 3 slotted positions to adjust the height. The slotted holes will fit over two bolts permanently attached to a building. When the tarp container is attached to a building 3 of the suspension units are eliminated. Another feature is the invention can be repaired or parts replaced using standard plumbing pipe that can be purchased at most lumber and plumbing merchandisers.

Abstract: Sodium chloride and purified water are recovered by treating salt water that contains sodium chloride with an integrated reverse osmosis and electrodialysis system, which includes an efficiency-enhancing feature that is one or more of the following: the use of univalent anion and univalent cation selective membranes in the electrodialysis unit; the addition of a nanofiltration unit to process the diluate from the electrodialysis unit; or operation of the electrodialysis unit at an elevated pressure. Magnesium and bromine can optionally be produced when the salt water contains these materials.

Abstract: A method of correcting a cam phaser system failure including detecting a cam phaser system fault and generating a control signal to correct said cam phaser system fault.

Abstract: A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34+CD38− cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34+ cells on HUBEC monolayers supplemented with GM-CSF+IL-3+IL-6+SCF+flt-3 ligand caused a 14.5-fold increase in total cells, an 6.6-fold increase in CD34+ cells, and, most remarkably, a 440-fold increase in CD34+CD38− cells after 7 days. Further, CFU-GM production increased 15.1-fold, BFU-E increased 8-fold, and CFU-Mix increased 5.2-fold. Optimal generation was dependent upon the continued presence of exogenous supplied cytokines. Moreover, we found that non-brain human endothelial cells isolated from the same donors supported neither the expansion nor the maintenance of human CD34+CD38− cells.

Abstract: A composition and method for preventing/reducing the severity of epithelial cytoxicity side effects such as alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy wherein a cyclin-dependent kinase II inhibitor is contemporaneously administered to the patient.

Abstract: The invention relates to a method for treating cancer including administering to a mammal therapeutically effective amounts of an anti-neoplastic agent and a PDE4 inhibitor, treatment combinations containing the same as well as a method for attenuating unwanted cancer treatment side effects including myelosuppression and mucositis.

Abstract: A method and apparatus for determining the switching states of a target wheel used in an internal combustion engine, the method including providing a camshaft, providing a target wheel having teeth coupled to the camshaft, providing a sensor to detect the teeth of the target wheel, providing a cam phaser to phase the camshaft relative to a crankshaft of the internal combustion engine, homing the cam phaser to a known position relative to the crankshaft, rotating the crankshaft and camshaft, detecting the switching of the teeth by the sensor, referencing switching information detected by the teeth to crankshaft position information to produce a calibration for the target wheel, and storing the calibration in a controller to be use for control of the internal combustion engine.

Abstract: An application deployment model for enterprise applications to enable such applications to be deployed to and executed from a globally distributed computing platform, such as an Internet content delivery network (CDN). According to the invention, application developers separate their Web application into two layers: a highly distributed edge layer and a centralized origin layer. In a representative embodiment, the edge layer supports a servlet container that executes a Web tier, typically the presentation layer of a given Java-based application. Where necessary, the edge layer communicates with code running on an origin server to respond to a given request. In an alternative embodiment, the edge layer supports a more fully-provisioned application server that executes both Web tier (e.g., presentation) and Enterprise tier application (e.g., business logic) components.

Abstract: An application deployment model for enterprise applications enables such applications to be deployed to and executed from a globally distributed computing platform, such as an edge server in an Internet content delivery network (CDN). In a representative embodiment, a CDN edge server supports application server code that executes a Web tier and/or Enterprise tier component of a given Java-based application. When multiple instances of the application server code are executed, given resources (e.g., memory, CPU, disk and network I/O) are monitored, and the application server instances are terminated or rate-limited to prevent over-utilization by any particular instance. In addition, a given application running in a given application server instance is restricted from taking certain actions, e.g., reading or writing from a file system, so that it cannot interfere with or access data from another customer's application.

Abstract: The present invention relates to human and porcine endothelial cell derived growth factors (EDHF) that contain one or a mixture of more than one endothelial cell proteins having a molecular weight greater than about 30 kDa. The EDHF is added to culture medium to expand tri-lineage pre-dendritic myleomonocytic progenitor cells and culture endothelial cells. The present invention also relates to a method of amplifying myeloid dendritic cell precursors both in vitro and in vivo. The EDHF is also used therapeutically to increase myeloid dendritic cell production in vivo to enhance the activity of vaccines.

Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by can

Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by ca

Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-Cl1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydmogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by c